Curasight has reported its Q3/21 quarterly report. The financial P&L is not of great importance for an upcoming biotech company, but it is encouraging to see Curasight being well capitalised, as new funding was secured during the quarter. By year-end, we expect the company to have more than DKK 70m in cash. Curasight is therefore well positioned to accelerate its plans for uTREAT (therapy) and uTRACE (diagnostic) further, in our view.

Link to the analysis